Revised Geneva Score Calculator

About the Revised Geneva Score Calculator

The Revised Geneva Score is a validated clinical prediction rule for estimating the pre-test probability of pulmonary embolism (PE). Unlike the Wells score, which includes the subjective criterion "PE is the most likely diagnosis," the Revised Geneva Score uses exclusively objective criteria, making it fully standardized and reproducible across different clinicians.

Developed by Le Gal et al. in 2006, the score uses 8 clinical variables: age, prior VTE, recent surgery or fracture, active malignancy, unilateral leg pain, hemoptysis, heart rate, and leg edema with deep vein tenderness. The total score stratifies patients into low (0-3), intermediate (4-10), and high (≥11) probability categories.

The Revised Geneva Score has been validated in multiple large multicenter studies and is endorsed alongside the Wells score for PE probability assessment. Its objective nature makes it particularly valuable for research, quality metrics, and settings where standardization is prioritized.

When This Page Helps

The key advantage of the Revised Geneva Score over the Wells score is its complete objectivity. No criterion requires the clinician to decide whether PE feels like the leading diagnosis, so inter-observer variability is lower.

This page is most useful as a risk-framing worksheet. It turns the standard 8 variables into one reproducible pretest-probability band without pretending the score alone decides D-dimer use, imaging, or treatment.

How to Use the Inputs

1. Assess patient age and select the appropriate range.
2. Evaluate each clinical risk factor (DVT/PE history, surgery, cancer, symptoms).
3. Record heart rate and select the appropriate range.
4. Examine the lower extremities for unilateral edema with deep vein tenderness.
5. Sum all points for the total score.
6. Use the score category as pretest-probability context within the broader PE workup.
7. Compare the result with D-dimer, imaging, and the rest of the clinical picture rather than using the score alone.

Example Calculation

Tips & Best Practices

• The Geneva score is fully objective — it produces the same result regardless of clinician experience or bias.
• For patients ≥50, use age-adjusted D-dimer (age × 10 μg/L) to reduce unnecessary CTA scans.
• Higher Geneva bands are stronger review context, not stand-alone medication or imaging orders.
• Always examine both legs — unilateral edema with deep vein tenderness provides high-value points (4 pts).
• The simplified Geneva score (all items = 1 point) is easier and has similar accuracy.
• Document the Geneva score and diagnostic pathway in the medical record for medicolegal protection.

How the Revised Geneva Score Fits into PE Review

The Revised Geneva Score is best used as an objective pretest-probability layer. It helps structure the early PE discussion before D-dimer, imaging, and the wider differential are fully integrated.

D-dimer and Imaging Context

Lower and intermediate score bands are often reviewed with D-dimer-first pathways, while higher score bands more often push the conversation toward imaging-first review. The exact sequence still depends on the local protocol, pregnancy status, hemodynamic stability, and the rest of the case.

Why the Score Matters

Because every variable is objective, the score is easier to standardize across clinicians and systems than gestalt-heavy tools. That makes it useful for pathways and documentation, but it still should not be mistaken for a complete PE management algorithm.

Frequently Asked Questions

• Should I use the Revised Geneva Score or the Wells Score?

  Both scores have similar diagnostic accuracy for PE. The Wells score is more widely used in North America, while the Revised Geneva Score is favored in Europe. Choose the Geneva score when objectivity is important (protocols, EMR decision support) and the Wells score when clinical gestalt adds value. Either is acceptable per ESC and ACEP guidelines.

• What about the simplified version?

  A simplified Revised Geneva Score assigns 1 point to each criterion (instead of variable weights). The simplified version is easier to calculate and has comparable accuracy: low (0-1), intermediate (2-4), high (≥5). It is commonly used in clinical practice and is validated in many studies.

• How does age affect the score?

  Age is a continuous risk factor for PE. The Geneva score uses cutoffs: ages 65-75 add 1 point, >75 adds 2 points. This reflects the exponential increase in PE incidence with age (from <1 per 1000 at age 30 to >5 per 1000 at age 80). Age-adjusted D-dimer thresholds (age × 10 μg/L) further improve the algorithm in elderly patients.

• Can the Geneva score be used in pregnant patients?

  The Revised Geneva Score has not been specifically validated in pregnancy. Pregnant patients have altered physiology (higher heart rate, changed hemostasis) and different PE risk profiles. Specific pregnancy PE algorithms using V/Q scan and compression ultrasonography are recommended.

• What defines "active malignancy"?

  Active malignancy means cancer diagnosed within the past 6-12 months, active treatment (chemotherapy, radiation), or metastatic/advanced disease. Cancer in remission for several years and adequately treated non-melanoma skin cancer generally do not count. Cancer-associated VTE has unique pathophysiology and treatment considerations.

• Does tachycardia from other causes affect the score?

  The score counts heart rate regardless of etiology. A patient tachycardic from fever, pain, or anxiety will score higher even if the tachycardia is not from PE. This is a limitation — but tachycardia from any cause in a patient where PE is considered warrants investigation, as PE often coexists with other conditions.